Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07313761 · ClinicalTrials.gov registry record · Phase 1
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
A Phase 1 study of Overweight and Obesity, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 349
- Enrollment target
- 4
- Study locations
NCT07313761: Active Phase 1 study of Overweight and Obesity, sponsored by Amgen.
NCT07313761 is a Phase 1 study of Overweight and Obesity that is active but no longer recruiting, run by Amgen. The registered enrollment target is 349 participants, above the 225-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (55% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07313761, a Phase 1 study of Overweight and Obesity, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 349 participants
- Enrollment target
- 4
- Study locations
Study Summary
The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
Conditions Studied
Interventions
- DRUG Maridebart Cafraglutide
Study Locations (4)
California
- Anaheim Clinical Trials - Anaheim
- CenExel Collaborative Neuroscience Research, LLC Los Alamitos - Los Alamitos
Florida
- Clinical Pharmacology Of Miami, LLC - Miami
Ohio
- Ohio Clinical Trials, Inc. - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2026-06-26 |
| Phase | Phase 1 |
What the registry record for NCT07313761 still lists
NCT07313761 is an interventional study that assigns participants to a tested intervention. The registered 349 participants enrollment target is mid-sized for trials with a published cap, above the 225-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (55% higher).
The record links to 1 condition, with Overweight and Obesity appearing as the primary indexed condition, and to 1 intervention - of which Maridebart Cafraglutide is the first listed.
NCT07313761 reports a single indexed study location in California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT07313761 about?
NCT07313761 is a clinical study titled "A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations". The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
What is the current status of trial NCT07313761?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 349 participants. The study started on 2025-12-15. Estimated completion is 2026-06-26.
What conditions does trial NCT07313761 study?
This clinical trial studies the following conditions: Overweight and Obesity.
What interventions are being tested in trial NCT07313761?
The interventions under investigation include: Maridebart Cafraglutide (DRUG).
Who is sponsoring clinical trial NCT07313761?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07313761 being conducted?
This trial has 4 study locations across California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight and Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07313761's enrollment target sits among peer trials
349 24th of 115 higher than 92 of 115 other Overweight and Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overweight and Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Human Models of Selective Insulin Resistance: Alpelisib, Part I
RECRUITING · Phase 1
-
Healthy Summer Learners
COMPLETED · Phase 1
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Breathing & Blood Pressure
RECRUITING
-
A Pilot Factorial Trial of an Integrated Lifestyle Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI